Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
Year: 2014
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, neoadjuvant therapy, adjuvant therapy, pathological complete response, pharmacokinetics, immunogenicity, adverse events, event-free survival, body weight, drug exposure, locally advanced breast cancer, inflammatory breast cancer, non-inferiority, infection, weight-based dosing
Open Access status: bronze
OpenAlex ID: W2115527794
